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Antipsychotic Effects of Quetiapine  
in Naturalistic Long Term Follow Up Study
ObjectiveaaThis study aimed to examine the effectiveness of quetiapine and the effects of 
dosage relates to its effectiveness on schizophrenia and schizoaffective disorder in a naturalis-
tic setting in Korean people.
MethodsaaThis study was a 24-week, open-label, non-comparative, naturalistic study of 
quetiapine in patients diagnosed with schizophrenia and schizoaffective disorder according 
to DSM-IV. We stratified the patients into mild [(clinical global impression severity (CGI-S) 
<4 at baseline)] and severe groups (CGI-S ≥4 at baseline). We investigated the response rate, de-
fined as clinical global impression improvement (CGI-I) ≤2, in the severe group and the ag-
gravation rate in the mild group using the last-observation-carried-forward (LOCF) and the 
Kaplan-Meier method (K-M). 
ResultsaaDuring the 24 weeks, 151 (18.4%) of the participants dropped out of the study. 
There was a significant decrease in the mean CGI-S score, from 4.5±1.1 at baseline to 2.8± 
1.1 at 24 weeks. The response rate of severe group was 54.5% (estimated by LOCF) and 73.3% 
(K-M estimated) at 24 weeks. All patients who completed the study had taken a mean que-
tiapine dosage of 507.9±245.9 mg daily. The decrease of CGI-S score in high-dose group (the 
maximum dose was 750 mg/d or above) was statistically significant than that in recommended-
dose group (the maximum dose was less than 750 mg/d). 
ConclusionaaThis study demonstrated the long-term effectiveness of quetiapine in the treat-
ment of schizophrenia and schizoaffective disorder in a naturalistic setting in Korean people. 
This study suggests that higher than recommended quetiapine dosages could be more effective 
in some patients.   Psychiatry Investig 2010;7:128-134
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Introduction
Many studies have shown that quetiapine was an effective and well tolerated with compa-
rable efficacy to typical antipsychotics, such as haloperidol. Quetiapine has been superior to 
placebo in the treatment of schizophrenia, at doses ranging from 50 to 750 mg/d.
1-3 Although 
there has been no difference in the overall efficacy of quetiapine compared to typical antipsy-
chotics in the treatment of schizophrenia,
4,5 quetiapine has had a positive impact on the impor-
tant domains of cognitive performance and negative/affective symptoms as well as positive 
symptoms.
1,4,6 In addition, recent studies have reported the efficacy of quetiapine to treat mood 
disorder as well as schizophrenia.
7-14 Patients with quetiapine showed a lesser prolactin (PRL) 
increase and reported fewer extrapyramidal symptoms (EPS) than patients with haloperidol.
4
The results of all the above-mentioned clinical trials suggested that quetiapine might have 
several advantages over typical antipsychotics in the treatment of schizophrenia and bipolar 
disorder. However, these clinical trial findings should be applied with caution to the usual 
care setting, because clinical trials are usually performed in controlled settings, with a limit-
ed number of patients, and over the short-term. To complement limitations of clinical trials, na-
online © ML CommJS Lee et al. 
   www.psychiatryinvestigation.org  129
turalistic studies can be done in more patients for a longer pe-
riod. Published naturalistic studies have reported uncertain 
results that the effectiveness of quetiapine did not differ from 
that of other atypical antipsychotics and was actually lower 
than that of olanzapine.
15-17
There is also some uncertainty regarding not just the effec-
tiveness of quetiapine but also its optimal dose. Although cur-
rent prescribing information recommends that quetiapine be 
administered at doses up to 750 mg/d (800 mg/d in the USA, Ca-
nada and Korea), there are some questions about the effective 
optimal dose of quetiapine in the treatment of schizophrenia. 
Recently, various published results have suggested that in some 
patients, dosages higher than recommended amount may be 
necessary to achieve the full therapeutic effect.
18,19
This study aimed to examine the overall effectiveness of 
quetiapine and to explore its optimal dose in the treatment of 
schizophrenia and schizoaffective disorder in a naturalistic 
setting in Korean people.
Methods
Study design
This study was conducted between April and November, 
2007, in 42 centers, with the approval of the appropriate insti-
tutional review boards. Minimal inclusion and exclusion crite-
ria were used in order to diminish the potential selection bias. 
The 860 enrolled patients received a series of evaluations: clini-
cal global impression improvement/severity (CGI-I/CGI-S), 
drug dosage, drug compliance, CGI-5 factor
20 and patient’s sati-
sfaction questionnaire. This evaluation was performed at base-
line, at week 2, 4 and then monthly until the end of the study 
(24 weeks). 
During the study, the patients received the recommended 
dose of quetiapine (150-750 mg/d), but the dose could be in-
creased beyond the recommended dose according to investi-
gator’s decision. There were no limitations on patients’ concomi-
tant medication use.
Patients
Each participant gave informed written consent before en-
tering the study. The investigators offered entry to patients with 
a clinical diagnosis of schizophrenia or schizoaffective disor-
der (DSM-IV) who were between the ages of 18 and 65 and, in 
the opinion of the investigators, did not have any other serious 
medical conditions.
Patients were ineligible for the study if they met any of the 
following exclusion criteria: 1) a clear history of serious adverse 
events due to quetiapine; 2) a clear history of non-response of 
quetiapine, in the investigators’ judgment; 3) inadequately con-
trolled diabetes; 4) clinically significant, severe neutropenia with 
an absolute neutrophil count below 1,500/mm3; 5) simultane-
ously participation in another clinical trial; and 6) probable non-
compliance with the visit schedule or other study procedures, 
based on the investigators’ opinion.
Effectiveness evaluations
We assessed the quetiapine’s treatment effectiveness using 
the CGI-I and CGI-S. Because there was little chance of impro-
vement in patients with mild symptoms at baseline, we strati-
fied the patients into two groups, mild or severe, using baseline 
severity as measured by the CGI-S, and evaluated the effective-
ness of quetiapine based on the response rate of severe group’s 
response rate and aggravation rate of the mild group. The severe 
group consisted of patients who were moderately ill or worse 
(CGI-S ≥4) at baseline, with the mild group consisting of the re-
maining patients. In addition, we defined response rate as the 
percentage of patients in the severe group having a CGI-I score 
of 2 or less on any visit (“very much improved” or “much im-
proved”). In the mild group, we defined the aggravation of symp-
toms as a CGI-I score ≥5 on any visit during the study.
The intention to treat (ITT) population included all patients 
who received at least one follow-up evaluation. Missing data 
for the ITT population were imputed using the last observation 
carried forward (LOCF) method. Primary objective of this st-
udy was to investigate the effectiveness of quetiapine by analy-
zing the response rate in the ITT population using the LOCF 
and the Kaplan-Meier (K-M) method to estimate the probabili-
ty of response at 24 weeks, including the inverse of the survival 
curve. Our secondary objectives were to explore the relation-
ship between quetiapine dosage pattern and patient response 
rate, time to response, and changes in the CGI-5 factor’s sub-
scale scores: positive, negative, depressive, excitement, and co-
gnitive subscale.
Data analysis
We performed the statistical analyses using SAS version 
9.1 for Windows (SAS Institute Inc., Cary, NC, USA), describ-
ed continuous variables using summary statistics, such as 
means, standard deviations, and ranges, and described categori-
cal variables using frequencies and percentages. For the analy-
sis of effectiveness, we estimated the response rate of patients 
in severe group using the LOCF and the K-M method. We used 
the K-M method to estimate the cumulative rate of response in 
consideration of the patients’ high dropout rate due to the long-
term follow-up. To analyze continuous changes from baseline, 
we used paired t-tests. Statistical significance was defined by 
p<0.05. All tests were two sided.
Results
Patient disposition and demographics
Of the 860 patients enrolled in this study, 821 patients re-
ceived at least one follow-up evaluation; these comprised the 
ITT population for the effectiveness analyses (Figure 1). The 130  Psychiatry Investig 2010;7:128-134
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mean age of the ITT population was 39.5 years (range: 18-65 
years), and 45.4% (n=373) were male. One hundred ninety-
three patients (23.5% of the ITT population) had never re-
ceived any prior antipsychotic medications (Table 1).
During the 24-week follow-up, 151 patients (18.4%) drop-
ped out of the study; 62.9% of these dropouts left within 8 
weeks. The most common reasons for the discontinuation 
from the study were follow-up loss (35.1%), lack of efficacy 
or withdrawal of consent (27.8%), and lack of compliance 
(12.6%). Dropout patients’ CGI-S scores at baseline were sig-
nificantly higher than those of patients who completed the stu-
dy (4.8±1.0 and 4.4±1.1, respectively; df=819, t=-3.3, p= 
0.001).
There was no prohibition of the concomitant use of psy-
chotropic medications during the study, including the use of 
antipsychotics, and 53.6%-57.5% of the study population re-
ceived at least one concomitant psychotropic medication at 
each visit during the study. The percentages who received 
antianxiety or anticholinergic drugs during the study were 
24.0%-27.2% and 13.3%-16.1%, respectively. The percentag-
es for concomitant use of antipsychotics was 9.1% (at base-
line), 12.3% (maximum rate during the study), and 11.8% (at 
24 weeks).
Effectiveness analyses
There was a significant decrease in mean CGI-S score, 
from 4.5±1.1 at baseline to 2.8±1.1 at 24 weeks (LOCF, 
paired t-test; df=820, t=-36.3, p<0.001). Because there was 
little chance of improvement in patients with mild symptoms 
at baseline, as described detail in the method section, all pa-
tients in the ITT group were divided into 2 groups according 
to baseline CGI-S score: the severe group (n=670, CGI-S ≥4) 
and the mild group (n=151, CGI-S ≤3). When estimated by 
the LOCF and the K-M method, the severe group’s response 
Table 1. Demographic characteristics of enrolled patients (N=821)
[Min-Max]
Age  (Mean±SD, year) 39.5±12.1 [18-65]
Gender  Male 373 45.4%
Female 448 54.6%
Onset age* (Mean±SD, year) 29.6±9.60 [14-63]
Diagnosis Schizophrenia, paranoid type 395 48.1%
Schizophrenia, catatonic type 003 00.4%
Schizophrenia, residual type 049 06.0%
Schizophrenia, undifferentiated type 209 25.5%
Schizoaffective disorder 165 20.1%
Taking any antipsychotics 
before entering the study†
Yes 627 76.5%
No 193 23.5%
Total number of patients: *N=775, †N=820
Figure 1. Disposition of participated pa-
tients in the study.
N=39
Excluded from the analysis of
effectiveness and tolerability
N=151 (Drop out patients)
- Follow-up loss (35.1%),
- Lack of efficacy, withdrawal of consent (27.8%)
- Lack of compliance (12.6%)
- Others (21.9%)
Visit 1 (week 0)
Enrolled patients at baseline
N=860
Visit 8 (week 24)
Patients completed the study
N=670
Visit 2 (week 2)
Patients who were received at
least one more evaluation
N=821JS Lee et al. 
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rates at 24 weeks were 54.5% and 73.3%, respectively [(95% 
confidence interval (CI); 69.5%-77.1%)](Figure 2). At 24 weeks, 
most patients in the mild group (n=148, 98.0%, LOCF) sh-
owed no clinically significant aggravation of symptoms.
Analysis of CGI-5 factors in ITT group showed that all the 
subscale scores of CGI-5 factors such as positive, negative, 
cognitive, depressive, and agitation domains significantly de-
creased between baseline and 24 weeks (Table 2).
Dose-effectiveness relationship
The mean doses prescribed to the patients were 244.7 mg/d 
on day 1 and 305.2 mg/d on day 4. After that, the mean dose 
increased to a peak dose of 537.8 mg/d at 8 weeks and then 
decreased slowly, to 508.3±245.75 mg/d at 24 weeks (Table 
3). The patients who completed the study took a mean dose of 
507.9±245.9 mg/d daily over the course of the study (mini-
mum 12.5-maximum 1,500 mg/d).
In the severe group, there was no significant difference in 
mean quetiapine dosage between responders and non-respond-
ers (536.9±217.9 and 567.9±247.5 mg/d, LOCF, respectively; 
df=557, t=-1.66, p=0.098).
To evaluate the effectiveness of quetiapine dosages above 
the recommended, we compared the changes in CGI-S be-
tween the high-dose group (maximum dose 750 mg/d or above) 
and the recommended-dose group (maximum dose less than 
750 mg/d). From baseline to 24 weeks, the CGI-S scores in the 
high-dose and recommended-dose groups decreased 2.19± 
1.44 and 1.70±1.29, respectively, and these changes were sig-
nificantly different between the groups after controlling for 
baseline CGI-S scores (ANCOVA; covariate-age, baseline CGI- 
S; F=-3.79, p<0.001). Mean doses during the study for the high- 
dose and recommended-dose groups were 745.2±164.7 and 
392.1±169.3 mg/d, respectively. In addition, we further strati-
fied the patients based on mean quetiapine dose during the 
study. The CGI-S scores of patients prescribed a mean dose 
of ≥750 mg/d were significantly decreased compared with 
those of patients prescribed a mean dose of <750 mg/d (AN-
COVA; covariate-age, baseline CGI-S; F=-4.42, p<0.001).
Patients’ satisfaction
We assessed the patients’ satisfaction with quetiapine at 4, 
12, and 24 weeks. There was a trend for patients’ satisfaction   
to gradually increase. The proportion of patients who express-
ed “very much satisfaction” increased from 17.0% at 4 weeks 
Table 2. The changes of clinical global impression-5 factor from baseline to 24 weeks
N
Baseline End point Statistical value
Mean±SD Mean±SD df t-value p-value*
Positive 791 4.27±1.27 2.47±1.13 790 -36.12 <0.0001
Negative 789 3.23±1.27 2.29±1.00 788 -20.55 <0.0001
Depression 791 3.08±1.27 2.08±1.01 790 -21.11 <0.0001
Cognition 788 3.05±1.35 2.05±1.03 787 -22.55 <0.0001
Excitation 787 3.38±1.54 1.84±1.00 786 -28.37 <0.0001
*Paired t-test using the last observation carried forward method
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Figure 2. The estimated cumulative re-
sponse rate of patients during 24 weeks 
follow-up using Kaplan-Meier method.132  Psychiatry Investig 2010;7:128-134
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to 40.3% at 24 weeks (Table 4). In addition, the patients’ satis-
faction at 24 weeks significantly increased compared with that 
at 4 weeks using Cochran-Mantel-Haenszel test (df=1, CMH 
value=188.97, p<0.0001).
Discussion
This naturalistic study showed the effectiveness of que-
tiapine to treat schizophrenia or schizoaffective disorder. The 
response rates of patients in the severe group were 54.5% and 
73.3% when estimated by the LOCF and the K-M method, re-
spectively. The fact that some patients experienced worsening 
symptoms (CGI-I >3) after having once shown a positive re-
sponse (CGI-I ≤2) at any visit, which means the K-M method 
counted these patients (n=154, 18.8%) in its response group 
but the LOCF included them in the non-response group, might 
explain this difference in response rates. The analysis, using 
LOCF imputation, was performed to estimate the response rate 
based on the CGI-I score at end point, irrespective of CGI-I 
scores before the end point. But K-M was performed to esti-
mate the response rate based on the CGI-I score at any visit; 
therefore, the response rate using the K-M method would gen-
erally be higher than that using the LOCF. However, although 
18.8% of patients showed a worsening of symptoms after they 
had shown a positive response at any one visit, the symptoms 
did not worsen to any serious extent. About 90% of wors-
ened patients had CGI-S scores of 3 (mild) or lower at study’s 
end. In addition, quetiapine was effective to treat the patients in 
the mild group. Only 2% of patients in the mild group experi-
enced an aggravation of their symptoms.   
To compare the effectiveness of quetiapine to that of the oth-
er antipsychotics, we compared our results with the published 
results of studies with similar protocols. The 26-week, natural-
istic, open study by Kerwin et al.
21 showed that the response 
rate (CGI-I ≤2, LOCF) were 44% and 34% in schizophrenic pa-
tients prescribed aripiprazole and another atypical antipsycho-
tic, respectively. According to the European Broad Effectiveness 
with aripiprazole (EU-BETA) study, 43% of schizophrenic 
patients showed positive responses (CGI-I ≤2) during the stu-
dy’s 8-week follow-up period.
22 These results showed the res-
ponse rate of quetiapine in our study was similar to that of oth-
er antipsychotics. This suggests antipsychotic efficacy of que-
tiapine is comparable to that of other atypical antipsychotics.
It is generally well-known that, within the recommended 
dose range, quetiapine is well-tolerated and clinically effective 
for the treatment of schizophrenia. According to the review of 
literature by Sparshatt et al.,
23 150-450 mg/d dosages of imme-
diate-release (IR) quetiapine are more effective than placebo 
treatment. Furthermore, this review showed IR quetiapine dos-
ages averaging between 254 and 525 mg/d are equivalent in ef-
ficacy to standard dosages of both conventional and other atyp-
ical antipsychotics. Some studies, however, have reported that 
higher than recommended doses of quetiapine were more ef-
fective in some patients with schizophrenia. Quetiapine dos-
ages above 750 mg/d have been well-tolerated and effective in 
some patients.
18 A 12-week open label trial of high dose que-
tiapine for patients with documented treatment-refractory 
schizophrenia showed that 4 (33%) of the patients responded 
Table 3. Treatment dose of quetiapine at any visit (mg/d)
N Mean±SD Median Min Max
Visit1 (baseline) 820 231.30±179.54 200 12.5 1,000
Visit2 (2 weeks) 779 451.70±258.50 400 250. 1,600
Visit3 (4 weeks) 760 525.87±267.83 550 12.5 1,800
Visit4 (8 weeks) 754 537.78±261.74 600 12.5 1,800
Visit5 (12 weeks) 721 532.99±246.98 600 12.5 1,400
Visit6 (16 weeks) 695 526.31±241.30 600 12.5 1,200
Visit7 (20 weeks) 678 519.45±242.18 500 12.5 1,500
Visit8 (24 weeks) 665 508.33±245.75 500 12.5 1,500
Table 4. Patients’ satisfaction with quetiapine
Visit3 Visit5 Visit8
df CMH value p-value*
N (%) N (%) N (%)
Very much 126 (17.03)0 200 (28.90)0 260 (40.25)0
1 188.97 <0.0001
Moderately 226 (30.54)0 298 (43.06)0 270 (41.80)0
Minimally 321 (43.38)0 178 (25.72)0 108 (16.72)0
Not at all 067 (9.05)00 016 (2.31)00 008 (1.24)00
Total 740 (100.00) 692 (100.00) 646 (100.00)
*Cochran-Mantel-Haenszel (CMH) test (comparison of visit3 and visit8)JS Lee et al. 
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to treatment during the study, in which all patients were ti-
trated to the target dose of 1,200±200 mg/d over a three-week 
period.
19 These studies showed that the patients receiving high-
er than recommended quetiapine dosages improved more than 
did patients receiving the recommended dose. Consistent with 
these studies, our findings, in which the patients who took more 
than the recommended dosage (mean or max dose ≥750 mg/d) 
improved significantly more than did the patients taking the 
recommended dose, suggest the possibility that higher than rec-
ommended dosages of quetiapine are more effective for treat-
ing schizophrenia or schizoaffective disorder.
This study had a general limitation of the open, non-compa-
rative study. Therefore, generalization of the results of this 
study beyond the sample population should be made cautious-
ly. Another limitation of this study was related to the concomi-
tant use of other antipsychotics in some patients. At any time 
during the study period, 145 (17.7%) patients (the concomitant 
group) were concomitantly taking other antipsychotics in addi-
tion to quetiapine. Most concomitant antipsychotics during 
the study were risperidone (n=42, 6.06±9.55 mg/day), olanza-
pine (n=9, 15.42±14.23 mg/day) and haloperidol (n=19, 5.64± 
3.74 mg/day). The number of patients who had taken concom-
itant antipsychotics at each visit ranged from 76 (at baseline) to 
92 (at 2 weeks) during the study. Although the baseline symp-
toms in the concomitant group were more severe than those in 
the non-concomitant group, who took quetiapine alone during 
the study (CGI-S scores 4.79±1.11 vs. 4.43±1.06; Student’s t-
test; df=819, t=-3.66, p<0.001), these two groups showed sig-
nificant improvements over time. Furthermore, the non-con-
comitant group showed similar symptom improvements when 
compared to the concomitant group. We obtained these similar 
results when we reanalyzed the data of patients who did not re-
ceive concurrent antipsychotics. 
In spite of these limitations, the major implications of this 
study are as follows: 1) Quetiapine is well-tolerated and effec-
tive for treating schizophrenia or schizoaffective disorder in 
the usual care setting; 2) Dosages of quetiapine above 750 mg/d 
may be more desirable than recommended dosages for some 
patients with schizophrenia or schizoaffective disorder.
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